ReutersBiogen, AbbVie drug slows MS episodes, safety issues recurReuters(Reuters) – A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the …Once-monthly MS drug from Biogen Idec, AbbVie clears Phase III hurdleFierceBiotechBiogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 …Wall Street JournalSuccessful Phase 3 results for daclizumabSeeking Alphaall 7 news articles …Read Full Story
Biogen, AbbVie drug slows MS episodes, safety issues recur - Reuters
Real Estate of Cebu
